|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||531.29 - 558.39|
|52-week range||517.00 - 852.25|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||51.24|
|Forward dividend & yield||3.01 (0.54%)|
|Ex-dividend date||09 May 2022|
|1y target est||N/A|
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
Lonza Group AG / Key word(s): Annual Results26-Jan-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad Hoc Release Pursuant to Art. 53 Listing Rules Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 2021 CAPEX reached 24% of sales, supporting long-term plan to deliver attractive margins through de-risked growth investments Contin
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.